EC Clinical and Medical Case Reports

Research Article Volume 3 Issue 4 - 2020

Rosacea and Chronic Systemic Diseases: Case-Control Study in Saudi Arabia

Norah AlOmair1, Yazeed AlHussan2, Mazen Alyahia1, Muhannad Alzahrani3, Nawaf Sallout1, Afnan Elahi1, Manal Hasan4 and Iqbal Bukhari1*

1Dermatology Department, College of Medicine, Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University, Dammam, Saudi Arabia

2Derma Clinics, Riyadh, Saudi Arabia

3Plastic Surgery Department, College of Medicine, Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University, Dammam, Saudi Arabia

4Internal Medicine Department, College of Medicine, Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University, Dammam, Saudi Arabia

*Corresponding Author: Iqbal Bukhari, Professor, Dermatology Department, College of Medicine, Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University, Dammam, Saudi Arabia
Received: February 28, 2020; Published: March 11, 2020




Objective: We sought to examine the association between rosacea and systemic comorbidities in patients attending the dermatology clinic at King Fahd Hospital of the University in Al-Khobar during a 14-month period (February 2016 to May 2017).

Methods: This was a prospective single-center case-control study conducted in the dermatology department of King Fahd Hospital of the University (KFHU) during a 14-month period. Self-administered questionnaires were distributed to rosacea patients and controls. The questionnaires examined demographic data, current comorbidities, family histories, and lifestyles. Study limitations were report and recall biases, which are major limitations of self-reported questionnaires.

Results: A total of 76 patients (38 cases and 38 controls) of Arabic origin were recruited in the study. The mean age was 33.2 years for the cases and 27.4 years for the controls. Positive p values were seen in family histories of rosacea, photosensitivity, and food allergies. Hypertension, cardiovascular, gastrointestinal, respiratory, genitourinary, and dermatological diseases and dyslipidemia were reported as associated comorbidities in rosacea patients.

Limitations: This was a case-control study with moderate sample size and associated medical conditions were self-reported confirmed either by medications use or medical records.

Conclusion: Rosacea is associated with numerous systemic comorbid diseases in our patients attending the dermatology clinic at King Fahd Hospital of the University.

Keywords: Rosacea; Comorbidities; Inflammation; Papulopustule; Photosensitivity

  1. Wilkin J., et al. “Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea”. Journal of the American Academy of Dermatology4 (2002): 584-587.
  2. Two AM., et al. “Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors”. Journal of the American Academy of Dermatology5 (2015): 749-758.
  3. Rainer B., et al. “Rosacea is associated with chronic systemic diseases in a skin severity dependent manner: Results of a case-control study”. Journal of the American Academy of Dermatology4 (2015): 604-608.
  4. Gether L., et al. “Incidence and prevalence of rosacea: a systematic review and meta-analysis”. British Journal of Dermatology2 (2018): 282-289.
  5. Parisi R and Yiu ZZ. “The worldwide epidemiology of rosacea”. British Journal of Dermatology2 (2018): 239.
  6. Spoendlin J., et al. “A study on the epidemiology of rosacea in the U.K”. British Journal of Dermatology3 (2012): 598-605.
  7. Hua TC., et al. “Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan”. Journal of the American Academy of Dermatology2 (2015): 249-254.
  8. Duman N., et al. “Rosacea and cardiovascular risk factors: a case control study”. Journal of the European Academy of Dermatology and Venereology9 (2014): 1165-1169.
  9. Egeberg A., et al. “Assessment of the risk of cardiovascular disease in patients with rosacea”. Journal of the American Academy of Dermatology2 (2016): 336-339.
  10. Egeberg A., et al. “Rosacea and gastrointestinal disorders: a population-based cohort study”. British Journal of Dermatology1 (2017): 100-106.
  11. Egeberg A., et al. “Nationwide assessment of cause-specific mortality in patients with rosacea: a cohort study in Denmark”. American Journal of Clinical Dermatology6 (2016): 673-679.
  12. Spoendlin J., et al. “Rosacea in patients with ulcerative colitis and Crohn’s disease: a population-based case control study”. Inflammatory Bowel Disease3 (2015): 680-687.
  13. Kim M., et al. “Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study”. Journal of the American Academy of Dermatology1 (2017): 40-48.
  14. Egeberg A., et al. “Exploring the association between rosacea and Parkinson disease: a Danish nationwide cohort study”. JAMA Neurology5 (2016): 529-534.
  15. Lyon S., et al. “LB766 Parkinson’s disease association with rosacea: a large, single center, retrospective study”. Journal of Investigative Dermatology8 (2016): B3.
  16. Egeberg MD., et al. “Patients with rosacea have increased risk of dementia”. Annals of Neurology6 (2016): 921-928.
  17. Egeberg A., et al. “Clustering of autoimmune diseases in patients with rosacea”. Journal of the American Academy of Dermatology4 (2016): 667-672.
  18. Akin Belli A., et al. “The relationship between rosacea and insulin resistance and metabolic syndrome”. European Journal of Dermatology3 (2016): 260-264.
  19. Aldrich N., et al. “Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins”. JAMA Dermatology11 (2015): 1213-1219.
  20. Egeberg A., et al. “Prevalence and risk of migraine in patients with rosacea: a population-based cohort study”. Journal of the American Academy of Dermatology3 (2017): 454-458.
  21. Li WQ., et al. “Personal history of rosacea and risk of incident cancer among women in the US”. British Journal of Cancer3 (2015): 520-523.
  22. Egeberg A., et al. “Association of rosacea with risk for glioma in a Danish nationwide cohort study”. JAMA Dermatology 152.5 (2016): 541-545.
  23. Egeberg A., et al. “Rosacea and risk of cancer in Denmark”. Cancer Epidemiology 47 (2017): 76-80.
  24. Aksoy B., et al. “Systemic comorbidities associated with rosacea: a multicentric retrospective observational study”. International Journal of Dermatology6 (2018): 722-728.
  25. Schwab VD., et al. “Neurovascular and neuroimmune aspects in the pathophysiology of rosacea”. Journal of Investigative Dermatology Symposium Proceedings1 (2011): 53-62.
  26. Steinhoff M., et al. “Clinical, cellular, and molecular aspects in the pathophysiology of rosacea”. Journal of Investigative Dermatology Symposium Proceedings1 (2011): 2-11.
  27. Buhl T., et al. “Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways”. Journal of Investigative Dermatology9 (2015): 2198-2208.
  28. Yamasaki K., et al. “Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea”. Nature Medicine8 (2007): 975-980.
  29. Yamasaki K., et al. “TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes”. Journal of Investigative Dermatology3 (2011): 688-697.
  30. Barresi C., et al. “Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection”. Journal of Investigative Dermatology1 (2011): 188-194

Iqbal Bukhari., et al. " Rosacea and Chronic Systemic Diseases: Case-Control Study in Saudi Arabia." EC Clinical and Medical Case Reports 3.4 (2020): 09-14.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net